# Moriah Nachbaur

> Moriah Katherine Nachbaur is the Chief Business Officer at Pheast Therapeutics, a clinical-stage immuno-oncology company in Redwood City, California, pioneering macrophage checkpoint inhibitors to teach the immune system to destroy cancer cells. Drawing on two decades of cross-functional biopharma experience - from lab benches at Genentech to executive boardrooms at Coherus BioSciences and her own consulting firm MKN Biotech - she brings a rare blend of scientific literacy, operational depth, and strategic vision to one of oncology's most promising new frontiers: the innate immune system's untapped power against solid tumors.

- **Role:** Chief Business Officer at Pheast Therapeutics
- **Organizations:** Pheast Therapeutics, MKN Biotech, Inc., Elixirgen Therapeutics, Coherus BioSciences, Genentech, New Ventures West, Mendel Biotechnology
- **Nationality:** American
- **Education:** A.B. in Biochemical Sciences, Harvard University, Graduate Coursework in Immunology and Cancer Biology, University of California, Berkeley, Graduate Certificate in Product Creation and Innovative Manufacturing, Stanford University, Secondary Education, Crystal Springs Uplands School, Secondary Education, The Nueva School, Integral Coaching Certification, New Ventures West
- **Known for:** Rose to SVP Product Development at Coherus BioSciences, serving on the Executive Committee, Built and ran MKN Biotech, Inc., her own biopharma consulting firm, as CEO and Principal, Helped guide Pheast Therapeutics through FDA Fast Track Designation for PHST001 for ovarian cancer (June 2025)

## Career timeline

- **2001** — Summer laboratory intern at Mendel Biotechnology, Inc.
- **2001-2005** — Studied Biochemical Sciences at Harvard University; worked as Laboratory Research Assistant in Dr. Raymond Erikson's Lab and Writing Tutor at Harvard Extension School
- **2006** — Joined Genentech in R&D / Translational Oncology as summer intern, then full-time employee
- **2006-2013** — Held numerous roles at Genentech spanning R&D, Early Development, Supply Chain & Manufacturing, Pricing & Contracting, and Commercial Launch
- **2013** — Joined Coherus BioSciences
- **2013-2018** — Rose through multiple roles at Coherus BioSciences including SVP Product Development; led Program Management and Regulatory Affairs as Executive Committee member
- **2019** — Founded MKN Biotech, Inc., a biopharma consulting firm specializing in integrated product development and corporate strategy
- **2022** — Appointed Chief Business Officer at Elixirgen Therapeutics (September 2022)
- **2024-2025** — Joined Pheast Therapeutics as Chief Business Officer

## Achievements

- Rose to SVP Product Development at Coherus BioSciences, serving on the Executive Committee
- Built and ran MKN Biotech, Inc., her own biopharma consulting firm, as CEO and Principal
- Helped guide Pheast Therapeutics through FDA Fast Track Designation for PHST001 for ovarian cancer (June 2025)
- Part of Pheast leadership team as company advanced PHST001 into Phase 1 clinical trials (April 2025)
- Gained cross-functional expertise spanning R&D, regulatory affairs, supply chain, business development, and commercial launch across top biopharma companies
- Certified Integral Coach through New Ventures West
- Harvard AB in Biochemical Sciences with lab experience in Translational Oncology

## Latest updates

- **2026-05** — Pheast Therapeutics presented preclinical data on PHST677, a novel bispecific ADC targeting CDH1 and Nectin-4, at PEGS Boston Summit 2026
- **2026-04** — Pheast reported initial Phase 1a data showing early clinical activity and target engagement for PHST001 at AACR 2026
- **2026-03** — Pheast advanced PHST001 into Phase 1b combination cohorts
- **2025-06** — FDA granted Fast Track Designation to PHST001 for treatment of ovarian cancer
- **2025-04** — First patient treated in PHST001 Phase 1 clinical trial for advanced solid tumors

## Links

- Website: https://pheast.com
- LinkedIn: http://www.linkedin.com/in/moriah-katherine-nachbaur
- Twitter/X: https://twitter.com/pheast_inc

---

Profile page: https://yespress.io/moriah-nachbaur
Published by YesPress — https://yespress.io
Last updated: 2026-05-13